Madeleine Duvic
Impact in
- Dermatology top 0.01%
- Cutaneous lymphoproliferative disorders research
- Pathology and Forensic Medicine top 0.02%
- Lymphoma Diagnosis and Treatment
Papers in
- Dermatology 450
- Cutaneous lymphoproliferative disorders research 400
-
- Lymphoma Diagnosis and Treatment 148
- Autoimmune Bullous Skin Diseases 33
- Co-authors
- Rakhshandra Talpur (42 shared papers)Youn H. Kim (39 shared papers)Xiao Ni (25 shared papers)Elise A. Olsen (23 shared papers)Victor Gerardo Prieto (61 shared papers)Razelle Kurzrock (14 shared papers)Chunlei Zhang (14 shared papers)Jenny Vu (5 shared papers)
- Journals
- Journal of the American Academy of Dermatology (80 papers)Blood (71 papers)Journal of Investigative Dermatology (38 papers)American Journal of Clinical Dermatology (18 papers)Journal of Clinical Oncology (14 papers)
- Partner nations
- United StatesUnited KingdomFrance
In The Last Decade
Madeleine Duvic
653 papers receiving 32.2k citations
Madeleine Duvic's Hit Papers
Peers
Comparison fields: 5 of 174
- Dermatology 17.9k
- Pathology and Forensic Medicine 9.7k
- Immunology 8.5k
- Urology 2.4k
- Oncology 6.0k
Countries citing papers authored by Madeleine Duvic
This map shows the geographic impact of Madeleine Duvic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Madeleine Duvic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Madeleine Duvic more than expected).
Fields of papers citing papers by Madeleine Duvic
This network shows the impact of papers produced by Madeleine Duvic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Madeleine Duvic. The network helps show where Madeleine Duvic may publish in the future.
Co-authors
The 25 scholars most cited alongside Madeleine Duvic, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 666 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) Hit paper breakdown → | 2007 | 1091 |
| 2 | Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Hit paper breakdown → | 2006 | 960 |
| 3 | Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma Hit paper breakdown → | 2007 | 871 |
| 4 | Alopecia areata investigational assessment guidelines–Part II Hit paper breakdown → | 2004 | 655 |
| 5 | Genome-wide association study in alopecia areata implicates both innate and adaptive immunity Hit paper breakdown → | 2010 | 652 |
| 6 | Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma Hit paper breakdown → | 2010 | 559 |
| 7 | Bexarotene Is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial Results Hit paper breakdown → | 2001 | 554 |
| 8 | Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer Hit paper breakdown → | 2011 | 547 |
| 9 | 2011 | 520 | |
| 10 | Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial Hit paper breakdown → | 2018 | 512 |
| 11 | Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma Hit paper breakdown → | 2001 | 499 |
| 12 | Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial Hit paper breakdown → | 2017 | 450 |
| 13 | 2002 | 354 | |
| 14 | Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model Hit paper breakdown → | 2015 | 334 |
| 15 | 1988 | 330 | |
| 16 | 2005 | 329 | |
| 17 | 2008 | 322 | |
| 18 | 2019 | 312 | |
| 19 | 2007 | 307 | |
| 20 | 2011 | 302 |
About Madeleine Duvic
Madeleine Duvic is a scholar working on Dermatology, Pathology and Forensic Medicine, Immunology, Oncology and Epidemiology, having authored 666 papers that have together received 33.6k indexed citations. Recurring topics across this work include Cutaneous lymphoproliferative disorders research (400 papers), Lymphoma Diagnosis and Treatment (148 papers), T-cell and Retrovirus Studies (105 papers), Fungal Infections and Studies (72 papers), Nail Diseases and Treatments (58 papers), CAR-T cell therapy research (46 papers), Autoimmune Bullous Skin Diseases (33 papers) and Hair Growth and Disorders (32 papers). The work is most often cited by research in Dermatology (17.9k citations), Pathology and Forensic Medicine (9.7k citations), Immunology (8.5k citations), Urology (2.4k citations) and Oncology (6.0k citations). Madeleine Duvic has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Rakhshandra Talpur, Youn H. Kim, Xiao Ni, Elise A. Olsen, Victor Gerardo Prieto, Razelle Kurzrock, Chunlei Zhang, Jenny Vu, Parul Hazarika and Michael T. Tetzlaff. Their work appears in journals such as Journal of the American Academy of Dermatology, Blood, Journal of Investigative Dermatology, American Journal of Clinical Dermatology and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.